|
SB-681323 is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA(Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.
|
